Patents by Inventor Charles C. Hong

Charles C. Hong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220202785
    Abstract: The invention relates to a class of small molecule inhibitors of GPR68/OGR1, a proton-sensing/stretch-sensing/sheer-stress-sending G-protein coupled receptor, and related receptors GPR4 and GPR65. These inhibitors are useful as a therapeutic for glioblastoma and other neoplasms, as a monotherapy or adjuvant, and also can be used as a treatment for other conditions, such as osteoporosis, inflammatory bowel disease, autoimmune and chronic inflammatory diseases such as multiple sclerosis and inflammatory pain syndromes, GERD, aspiration pneumonitis, bacterial and viral pneumonia, COPD, acute respiratory distress syndrome (ARDS), and COVID-19.
    Type: Application
    Filed: April 17, 2020
    Publication date: June 30, 2022
    Inventors: Charles C. HONG, Charles H. Williams, Latur Ravithej SINGH
  • Patent number: 10745400
    Abstract: Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted imidazo[1,2-a]pyridines.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 18, 2020
    Assignees: Vanderbuilt University, La Jolla Pharmaceuticals Company
    Inventors: Corey R. Hopkins, Matthew Ritter, Charles C. Hong, Anish Vadukoot, Darren W. Engers, Craig W. Lindsley
  • Publication number: 20200054643
    Abstract: The present invention provides small molecule inhibitors of BMP signaling that are useful for treating diseases or conditions associated with BMP signaling, including cancers of the central nervous system.
    Type: Application
    Filed: January 18, 2018
    Publication date: February 20, 2020
    Inventors: Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers
  • Publication number: 20190284183
    Abstract: Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted imidazo[1,2-a]pyridines.
    Type: Application
    Filed: March 14, 2019
    Publication date: September 19, 2019
    Inventors: Corey R. Hopkins, Matthew Ritter, Charles C. Hong, Anish Vadulkoot, Darren Engers, Craig W. Lindsley
  • Publication number: 20190218214
    Abstract: Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted imidazo [1,2-a] pyridines.
    Type: Application
    Filed: September 14, 2017
    Publication date: July 18, 2019
    Inventors: Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers
  • Patent number: 10329304
    Abstract: Compounds and compositions, and methods of use thereof, are provided and have utility in inhibiting hedgehog signaling and/or phosphodiesterase-4 activity.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: June 25, 2019
    Assignee: Vanderbilt University
    Inventors: Charles C. Hong, Charles H. Williams, Jonathan Hempel, T K Feaster, Don H. Rubin, Gary Sulikowski, Jijun Hao, Audrey Frist
  • Patent number: 10196392
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: February 5, 2019
    Assignee: Vanderbilt University
    Inventors: Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers
  • Publication number: 20170313701
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Application
    Filed: July 17, 2017
    Publication date: November 2, 2017
    Inventors: Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers
  • Patent number: 9738636
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 22, 2017
    Assignee: Vanderbilt University
    Inventors: Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers
  • Publication number: 20170190717
    Abstract: Compounds and compositions, and methods of use thereof, are provided and have utility in inhibiting hedgehog signaling and/or phosphodiesterase-4 activity.
    Type: Application
    Filed: March 7, 2017
    Publication date: July 6, 2017
    Inventors: Charles C. Hong, Charles H. Williams, Jonathan Hempel, TK Feaster, Don H. Rubin, Gary Sulikowski, Jijun Hao, Audrey Frist
  • Patent number: 9505763
    Abstract: Methods for regulating cancer cell growth and survival, inhibiting cancer cell growth, promoting cancer cell death, and/or treating a cancer make use of antagonists of a type I BMP receptor. In some embodiments the cancer is a lung cancer and the cancer cell is a lung cancer cell.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: November 29, 2016
    Assignees: Vanderbilt University, Rutgers, The State University of new Jersey
    Inventors: Charles C. Hong, John Langenfeld
  • Publication number: 20160068525
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 10, 2016
    Applicant: Vanderbilt University
    Inventors: Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers
  • Patent number: 9045484
    Abstract: The present invention provides pyridinyl-substituted pyrazolyl pyrimidine small molecule inhibitors of bone morphogenetic protein (BMP) signaling having the structure of formula (I), wherein variables A, B, E, F, X, Y, Z, Ar, L1, R4 and R15 are as defined in the specification. The compounds of the invention are useful in modulating cell growth, differentiation, proliferation, and apoptosis, and thus are useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: June 2, 2015
    Assignees: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
  • Patent number: 9040694
    Abstract: The presently-disclosed subject matter relates to compounds of the formula: and methods for use thereof. The presently-disclosed subject matter relates methods of selectively differentiating a stem cell, and methods of screening for compounds useful for enhancing terminal differentiation of committed cardiac progenitor cells.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: May 26, 2015
    Assignee: Vanderbilt University
    Inventors: Charles C. Hong, Corey R. Hopkins, Antonis K. Hatzopoulos, Craig W. Lindsley, Jijun Hao
  • Publication number: 20140256720
    Abstract: Methods for regulating cancer cell growth and survival, inhibiting cancer cell growth, promoting cancer cell death, and/or treating a cancer make use of antagonists of a type I BMP receptor. In some embodiments the cancer is a lung cancer and the cancer cell is a lung cancer cell.
    Type: Application
    Filed: July 25, 2012
    Publication date: September 11, 2014
    Applicants: UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY, VANDERBILT UNIVERSITY
    Inventors: Charles C. Hong, John Langenfeld
  • Patent number: 8822684
    Abstract: The presently-disclosed subject matter relates to compounds of the formula: and methods for use thereof. The presently-disclosed subject matter relates methods of selectively differentiating a stem cell, and methods of screening for compounds useful for enhancing terminal differentiation of committed cardiac progenitor cells.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: September 2, 2014
    Assignee: Vanderbilt University
    Inventors: Charles C. Hong, Corey R. Hopkins, Antonis K. Hatzopoulos, Craig Lindsley, Jijun Hao
  • Publication number: 20140011805
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Application
    Filed: July 12, 2013
    Publication date: January 9, 2014
    Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
  • Patent number: 8507501
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: August 13, 2013
    Assignees: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
  • Publication number: 20110053930
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Application
    Filed: March 13, 2009
    Publication date: March 3, 2011
    Applicants: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
  • Publication number: 20100093760
    Abstract: The invention provides methods for identifying compounds that modulate cell signaling, as well as therapeutic methods that employ such compounds.
    Type: Application
    Filed: September 12, 2007
    Publication date: April 15, 2010
    Applicant: The General Hospital Corporation
    Inventors: Paul B. Yu, Charles C. Hong, Kenneth D. Bloch, Randall T. Peterson